	US 12,252,459 B2
	Hydrazone amide derivatives and use thereof in preparation of anti-osteoporosis drugs
Dane Huang, Guangdong (CN); Chao Zhao, Guangdong (CN); Qiong Gu, Guangdong (CN); and Jun Xu, Guangdong (CN)
Assigned to SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD., Guangdong (CN)
Filed by SHENZHEN CELL INSPIRE PHARMACEUTICAL DEVELOPMENT CO., LTD., Guangdong (CN)
Filed on Dec. 27, 2021, as Appl. No. 17/562,040.
Application 17/562,040 is a continuation of application No. PCT/CN2020/083067, filed on Apr. 2, 2020.
Claims priority of application No. 201910578809.5 (CN), filed on Jun. 28, 2019.
Prior Publication US 2022/0153688 A1, May 19, 2022
Int. Cl. A61P 19/10 (2006.01); A61K 31/15 (2006.01); A61K 31/426 (2006.01); A61K 31/428 (2006.01); A61K 31/4465 (2006.01); A61K 31/472 (2006.01); A61K 31/5375 (2006.01); A61P 19/08 (2006.01); C07C 251/76 (2006.01); C07D 211/58 (2006.01); C07D 213/75 (2006.01); C07D 213/80 (2006.01); C07D 213/84 (2006.01); C07D 217/06 (2006.01); C07D 277/56 (2006.01); C07D 277/82 (2006.01); C07D 295/185 (2006.01); C07D 417/12 (2006.01)

CPC C07C 251/76 (2013.01) [A61K 31/15 (2013.01); A61K 31/426 (2013.01); A61K 31/428 (2013.01); A61K 31/4465 (2013.01); A61K 31/472 (2013.01); A61K 31/5375 (2013.01); A61P 19/08 (2018.01); A61P 19/10 (2018.01); C07D 211/58 (2013.01); C07D 213/75 (2013.01); C07D 213/80 (2013.01); C07D 213/84 (2013.01); C07D 217/06 (2013.01); C07D 277/56 (2013.01); C07D 277/82 (2013.01); C07D 295/185 (2013.01); C07D 417/12 (2013.01)]

2 Claims

1. A method for treating or preventing osteoporosis or osteopenia, the method comprising: administering a compound having one of the following structures or a stereoisomer, geometric isomer, tautomer, nitrogen oxide, hydrate, or solvate thereof, or a pharmaceutically acceptable salt or prodrug of the compound having one of the following structures to a patient: